Trial Profile

Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 03 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Elagolix (Primary) ; Estradiol/norethisterone
Indications Menorrhagia; Uterine leiomyoma
Focus Registrational; Therapeutic Use
Acronyms ELARIS UF-EXTEND
Sponsors AbbVie

Most Recent Events

01 Jun 2020 Results published in the Obstetrics and Gynecology
27 Apr 2020 Primary endpoint has been met. (Percentage of Responders based on menstrual blood loss volume reduction)
27 Apr 2020 Results presented at the 69th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com